Author argues SLS is a manipulated pre-revenue biotech whose positive leukemia survival data and rising institutional ownership leave short sellers exposed.
SLS — LONG The author claims SELLAS Life Sciences (SLS) is undervalued because naked short selling and warrant-related dilution suppress the stock after positive catalysts like prolonged leukemia survival data and rare pediatric disease designation. He argues shorts have not covered and are 'in serious trouble' as institutional ownership rises and misinformation is corrected. The near-term catalyst is updated short interest data, while the main stated risk is inherent small-cap biotech dilution and cash burn.
Shorts resorting to misinformation indicates they are in serious trouble!
This Reddit post, published January 11, 2026, features u/Yung_Ceejay discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Yung_Ceejay · Tickers: SLS